Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without any commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent statements from Peptron confirming ongoing joint research on multiple candidates have not produced evidence of commercial negotiations, and Lilly’s parallel pursuit of oral obesity candidates adds further uncertainty. With only weeks remaining before the October 7 resolution date, the absence of any disclosed commercial framework underpins the market’s strong consensus against a near-term license.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật13% khả năng
$11,264 KL.
$11,264 KL.
Oct 7, 2026
13% khả năng
$11,264 KL.
$11,264 KL.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without any commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent statements from Peptron confirming ongoing joint research on multiple candidates have not produced evidence of commercial negotiations, and Lilly’s parallel pursuit of oral obesity candidates adds further uncertainty. With only weeks remaining before the October 7 resolution date, the absence of any disclosed commercial framework underpins the market’s strong consensus against a near-term license.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Thị trường mở: May 5, 2026, 8:02 PM ET
Khối lượng
$11,264Ngày kết thúc
Oct 7, 2026Thị trường mở
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without any commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent statements from Peptron confirming ongoing joint research on multiple candidates have not produced evidence of commercial negotiations, and Lilly’s parallel pursuit of oral obesity candidates adds further uncertainty. With only weeks remaining before the October 7 resolution date, the absence of any disclosed commercial framework underpins the market’s strong consensus against a near-term license.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Khối lượng
$11,264Ngày kết thúc
Oct 7, 2026Thị trường mở
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive evaluation rights to SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for one- to six-month sustained peptide release, without any commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. Recent statements from Peptron confirming ongoing joint research on multiple candidates have not produced evidence of commercial negotiations, and Lilly’s parallel pursuit of oral obesity candidates adds further uncertainty. With only weeks remaining before the October 7 resolution date, the absence of any disclosed commercial framework underpins the market’s strong consensus against a near-term license.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp